Convalescent Plasma / Tabriz University of Medical Sciences - LARVOL DELTA

Therapeutic Impact of Tocilizumab in the Setting of Severe COVID-19; an Updated and Comprehensive Review on Current Evidence. (PubMed, Arch Acad Emerg Med) - "There are limited data on TCZ combination therapies, such as hemoperfusion, intravenous immunoglobulin (IVIG), simple O2 therapy, vasopressor support, convalescent plasma therapy, and even in vaccinated patients and COVID-19 reinfection, especially in elderly persons. Personalized medicine based on individual characteristics and pertinent clinical conditions must be considered in the clinicians' decision-making policy. Finally, to mitigate the risk-to-benefit ratio of TCZ, a treatment algorithm, based on available literature and updated national institute of health (NIH) and Infectious Diseases Society of America (IDSA) guidelines, is also proposed."

Journal • Review • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

Convalescent Blood: Current Perspective on the Efficacy of a Legacy Approach in COVID-19 Treatment. (PubMed, Blood Purif) - "Following a successful trial, this new approach of contemporary nature to a viral disease may serve as an emergency intervention to intercept infectious outbreaks and prevent an impending epidemic/pandemic. In this review, we document the most recent evidence regarding the efficiency of convalescent plasma and serum therapy on SARS, MERS, and particularly COVID-19, while discussing potential advantages and possible risks of such practice."

Clinical • Journal • Review • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases